Roche
Last updated Jul 2, 2026
Evidence Sources
15
Competitive Findings
6
Portfolio Developments
116
Regulatory Precedents
8
Clinical Programs
8
Confidence Coverage
64%
Audit
- Competitor findings: 6
- Portfolio developments: 116
- Self-competition findings removed: 227
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- KRAS Inhibitor
- Bispecific T-cell Engager
- Lung Cancer
- Solid Tumors
Highest priority development: Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease
Portfolio development
Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease is an owned Roche portfolio development in Neurology · Alzheimer's Disease.
Competitive pressure: High
Portfolio impact: High
Evidence coverage: 64%
Active Signals
206
Investigate Priority
30
Opportunity Score
144264
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- EscalateJul 2, 2026Score 711Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Oncology · KRAS G12C NSCLC
- EscalateJul 2, 2026Score 710Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Oncology · KRAS G12C Non-Small Cell Lung Cancer
- InvestigateJun 17, 2026Score 710STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism
Oncology · Breast Cancer
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Low Confidence · 0%Sources (3)RocheClinicalTrials.govPortfolio
- Low Confidence · 0%Sources (3)RocheClinicalTrials.govPortfolio
- Low Confidence · 0%Sources (3)Humanexa SignalsClinicalTrials.govPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
- FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupusModerate Confidence · 80%
Elevated competitive pressure
Sources (2)RocheCompetitiva - FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupusModerate Confidence · 65%
Elevated competitive pressure
Sources (2)RocheCompetitiva - FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupusModerate Confidence · 65%
Elevated competitive pressure
Sources (2)RocheCompetitiva
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumorsModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Verified Clinical Benefit | Cancer Accelerated ApprovalsModerate Confidence · 65%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical DevelopmentModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Ongoing | Cancer Accelerated ApprovalsModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupusModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupusModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupusModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancerModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- EscalateScore 711Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Oncology · KRAS G12C NSCLC
- EscalateScore 710Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Oncology · KRAS G12C Non-Small Cell Lung Cancer
- InvestigateScore 710STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism
Oncology · Breast Cancer
- InvestigateScore 708RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Roche right now?
- Which regulatory precedents should Roche monitor in Oncology and KRAS Inhibitor?
- How does Saphnelo compare to the nearest competitive programs?
- What signals require immediate investigation for Roche?
- Summarize the strategic implications of recent developments for Roche.
- Where is the greatest uncertainty in Roche's competitive positioning?